Clinical benefits of androgen receptor signaling inhibitors in patients with metastatic hormone-sensitive prostate cancer: real-world data from a multi-center study.
Kinoshita Y, Yamada Y, Tsujino T, Xue Z, Sato K, Saito S, Nishimura K, Fukushima T, Nakamura K, Yamamoto S, Arai T, Sato H, Higuchi K, Takei A, Kanesaka M, Ando K, Pae S, Kanaoka S, Takeshita N, Yoneda K, Hino D, Sazuka T, Imamura Y, Mikami K, Nakamura K, Fukasawa S, Kurozumi A, Naya Y, Nagata M, Komaru A, Tobe T, Suzuki N, Azuma H, Ichikawa T, Sakamoto S.
Kinoshita Y, et al. Among authors: pae s.
Jpn J Clin Oncol. 2025 Aug 3;55(8):954-962. doi: 10.1093/jjco/hyaf079.
Jpn J Clin Oncol. 2025.
PMID: 40382671